 |
|
Augmentation of Exposure Therapy With D-Cycloserine for Social Anxiety Disorder
Stefan G. Hofmann, PhD;
Alicia E. Meuret, PhD;
Jasper A. J. Smits, PhD;
Naomi M. Simon, MD, MSc;
Mark H. Pollack, MD;
Katherine Eisenmenger, MD;
Michael Shiekh, MD;
Michael W. Otto, PhD
Arch Gen Psychiatry. 2006;63:298-304.
Context Social anxiety disorder (SAD) is common and debilitating. Although exposure therapy is one of the most effective forms of psychotherapy for this disorder, many patients remain symptomatic. Fear reduction in exposure therapy is similar to extinction learning, and early clinical data with specific phobias suggest that the treatment effects of exposure therapy for SAD may be enhanced with D-cycloserine, an agonist at the glutamatergic N-methyl-D-aspartate receptor.
Objective To determine whether short-term treatment with 50 mg of D-cycloserine enhances the efficacy of exposure therapy for SAD.
Design Randomized, double-blind, placebo-controlled augmentation trial examining the combination of D-cycloserine or pill placebo with exposure therapy for SAD.
Setting Patients were self-referred from the general community to 1 of 3 research clinics.
Participants Twenty-seven participants meeting DSM-IV criteria for SAD with significant public speaking anxiety.
Interventions Following a diagnostic interview and pretreatment assessment, participants received 5 therapy sessions delivered in either an individual or group therapy format. The first session provided an introduction to the treatment model and was followed by 4 sessions emphasizing exposure to increasingly challenging public speech situations with videotaped feedback of performances. One hour prior to each session, participants received single doses of D-cycloserine or placebo.
Main Outcome Measures Symptoms were assessed by patient self-report and by clinicians blind to the randomization condition before treatment, after treatment, and 1 month after the last session.
Results Participants receiving D-cycloserine in addition to exposure therapy reported significantly less social anxiety compared with patients receiving exposure therapy plus placebo. Controlled effect sizes were in the medium to large range.
Conclusion The pilot data provide preliminary support for the use of short-term dosing of D-cycloserine as an adjunctive intervention to exposure therapy for SAD.
Author Affiliations: Department of Psychology and Center for Anxiety and Related Disorders, Boston University (Drs Hofmann, Meuret, Eisenmenger, and Otto) and Department of Psychiatry, Harvard Medical School and Massachusetts General Hospital (Drs Simon, Pollack, and Otto), Boston; and Department of Psychology, Southern Methodist University, Dallas, Tex (Drs Smits and Shiekh).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
The NMDA Agonist D-Cycloserine Facilitates Fear Memory Consolidation in Humans
Kalisch et al.
Cereb Cortex 2008;0:bhn076v1-bhn076.
ABSTRACT
| FULL TEXT
Critical Parameters for D-Cycloserine Enhancement of Cognitive-Behaviorial Therapy for Obsessive-Compulsive Disorder
Rothbaum
Am. J. Psychiatry 2008;165:293-296.
FULL TEXT
Augmentation of Behavior Therapy With D-Cycloserine for Obsessive-Compulsive Disorder
Wilhelm et al.
Am. J. Psychiatry 2008;165:335-341.
ABSTRACT
| FULL TEXT
Affective neuroscience and psychiatry
Harrison and Critchley
Br. J. Psychiatry 2007;191:192-194.
ABSTRACT
| FULL TEXT
D-Cycloserine enhances memory consolidation of hippocampus-dependent latent extinction
Gabriele and Packard
Learn. Mem. 2007;14:468-471.
ABSTRACT
| FULL TEXT
Converging Cognitive Enhancements
SANDBERG and BOSTROM
Ann. N. Y. Acad. Sci. 2006;1093:201-227.
ABSTRACT
| FULL TEXT
Evidenced-Based Time-Limited Treatment of Co-occurring Substance-Use Disorders and Civilian-Related Posttraumatic Stress Disorder
Back et al.
BRIEF TREAT CRISIS INTERVEN 2006;6:283-294.
ABSTRACT
| FULL TEXT
|
